Physician profile
Andre G Vendryes
NPI 1194708669
$3,095.06
in general payments reported to CMS, 2019-2025
31 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $975 · 2021: $22.43 · 2022: $99.99 · 2024: $170 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.00 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $347.28 | 2019-2020 | |
| Amgen INC. | $318.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $306.92 | 2019-2020 | |
| Astellas Pharma US INC | $287.33 | 2019-2022 | |
| Amarin Pharma, INC. | $224.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $223.15 | 2019-2020 | |
| Atricure, INC. | $170.00 | 2024 | |
| Daiichi Sankyo INC. | $142.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $119.48 | 2019-2020 | |
| Pfizer INC. | $118.67 | 2019-2020 | |
| Lilly USA, LLC | $99.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $94.18 | 2019-2020 | |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.02 | 2019-2025 | Jardiance |
| Sanofi Pasteur INC. | $54.40 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $50.08 | 2020 | |
| Tosoh Bioscience, INC. | $50.00 | 2019 | |
| Abbott Laboratories | $41.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $40.81 | 2019 | |
| Seqirus USA INC | $36.31 | 2019-2020 | |
| Bioventus LLC | $24.59 | 2020 | |
| Bausch Health US, LLC | $23.51 | 2020 | |
| Arbor Pharmaceuticals, INC. | $23.08 | 2019 | |
| Vivus LLC | $21.07 | 2019 | |
| Allergan, INC. | $19.30 | 2020 | |
| Vertiflex, INC. | $19.19 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.63 | 2020 | |
| Esperion Therapeutics, INC. | $17.06 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.45 | 2019 | |
| Genentech USA, INC. | $15.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Vendryes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.